Panel voted 18-4 with one abstention to recommend approval of Arena's lorcaserin, concluding its benefits "outweigh the potential risks when used long term" in overweight and obese people
Read More »Panel voted 18-4 with one abstention to recommend approval of Arena's lorcaserin, concluding its benefits "outweigh the potential risks when used long term" in overweight and obese people
Read More »